Limits...
Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H - Int. J. Cancer (2014)

Bottom Line: The COX2 rs5277 (306G>C) polymorphism has been associated with inflammation-associated cancers.Minor allele(C) frequency was 16.1%.Chemotherapy-treated G/G-carriers with a breast volume ≥ 850 ml had an increased risk of early events irrespective of ER status, adjusted HR 8.99 (1.14-70.89).

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Show MeSH

Related in: MedlinePlus

Flow chart of the selection process of patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4225481&req=5

fig01: Flow chart of the selection process of patients.

Mentions: Patients who had received preoperative treatment (n = 42) (including one patient who had no information regarding interstitial laser thermotherapy and one patient who presented with and received treatment for another cancer between the initial surgery and reoperation), who were diagnosed with carcinoma in situ (n = 14), and/or had metastases detected earlier than 3 months after study inclusion (n = 2), were excluded from the survival analyses. A flowchart of patients included and excluded in the analyses is presented in Figure 1. After exclusion, 86 of the included patients were diagnosed with some type of breast cancer event (ipsi/contralateral, regional or distant metastasis) during the 9-year follow-up time period; 54 of these patients had distant metastases. The median follow-up time was 5.1 years (IQR 3.0–7.1 years) for the 570 genotyped patients with invasive tumors and no distant metastasis detected on the postoperative metastasis screen.


Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H - Int. J. Cancer (2014)

Flow chart of the selection process of patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4225481&req=5

fig01: Flow chart of the selection process of patients.
Mentions: Patients who had received preoperative treatment (n = 42) (including one patient who had no information regarding interstitial laser thermotherapy and one patient who presented with and received treatment for another cancer between the initial surgery and reoperation), who were diagnosed with carcinoma in situ (n = 14), and/or had metastases detected earlier than 3 months after study inclusion (n = 2), were excluded from the survival analyses. A flowchart of patients included and excluded in the analyses is presented in Figure 1. After exclusion, 86 of the included patients were diagnosed with some type of breast cancer event (ipsi/contralateral, regional or distant metastasis) during the 9-year follow-up time period; 54 of these patients had distant metastases. The median follow-up time was 5.1 years (IQR 3.0–7.1 years) for the 570 genotyped patients with invasive tumors and no distant metastasis detected on the postoperative metastasis screen.

Bottom Line: The COX2 rs5277 (306G>C) polymorphism has been associated with inflammation-associated cancers.Minor allele(C) frequency was 16.1%.Chemotherapy-treated G/G-carriers with a breast volume ≥ 850 ml had an increased risk of early events irrespective of ER status, adjusted HR 8.99 (1.14-70.89).

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Show MeSH
Related in: MedlinePlus